
CSTL Stock Forecast & Price Target
CSTL Analyst Ratings
Bulls say
Castle Biosciences Inc. has demonstrated impressive growth metrics, particularly with its TissueCypher test, which experienced a 92% year-over-year increase in test volume in 2Q25, indicating strong market demand and effective sales force expansion. The company has also maintained robust profit margins, with TissueCypher achieving gross margins of 77% in Q3, reflecting the financial health and efficiency of its operations. As the gastrointestinal sales force matures in the second half of 2025, the potential for continued revenue growth from TissueCypher is strong, positioning Castle Biosciences favorably within its market segments.
Bears say
Castle Biosciences Inc. faces a negative outlook due to a projected decline in revenue multiples for its dermatology and DecisionDx-UM tests, primarily driven by the DecisionDx-Melanoma product, which is expected to be lower than those for TissueCypher. Despite indications that the stock appears undervalued in various scenarios, management has acknowledged significant barriers to market penetration, specifically the lack of awareness among clinicians in the gastroenterology sector regarding their tests. Additionally, it is believed that investor sentiment currently underestimates the challenges associated with expanding awareness and adoption of Castle's key test solutions.
This aggregate rating is based on analysts' research of Castle Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
CSTL Analyst Forecast & Price Prediction
Start investing in CSTL
Order type
Buy in
Order amount
Est. shares
0 shares